The transition to next-generation propellants (NGPs) is accelerating across the respiratory industry. Yet moving to an NGP-based pressurised metered dose inhaler (pMDI) is not a simple propellant substitution. Differences in physicochemical properties may affect formulation behaviour, aerosol performance, material compatibility, filling operations and regulatory strategy, creating development and scale-up risks if these interactions are not considered early.
This educational webinar will examine the technical and business choices that shape a successful NGP pMDI transition. It will explain why pMDIs remain critical for asthma and COPD treatment, review the evolving NGP landscape and explore why formulation, metering-valve, actuator and container-closure decisions must be assessed as an interconnected system.
The speakers will also discuss approaches for evaluating product performance, identifying compatibility risks and building manufacturing and regulatory readiness. Attendees will gain a clearer view of where risks can emerge and how predictive science, early testing and integrated development planning can support more informed decisions.
Register to hear Aptar Pharma experts share practical perspectives on de-risking the NGP transition while maintaining product performance, patient access and commercial readiness.
Key Learning Objectives
- Understand why the NGP transition should be managed as a system change rather than a drop-in propellant replacement.
- Identify how propellant properties can influence formulation behaviour, aerosol performance, device and material compatibility.
- Recognise the manufacturing, scale-up, regulatory and comparability considerations that should be addressed early in development.
- Explore practical approaches to de-risk NGP pMDI development through integrated device, formulation and performance evaluation.
